Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression - PubMed (original) (raw)
. 1999 Feb 15;162(4):2095-102.
Affiliations
- PMID: 9973483
Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression
S K Manna et al. J Immunol. 1999.
Abstract
Leflunomide is a novel immunosuppressive and antiinflammatory agent currently being tested for treatment of autoimmune diseases and transplant rejection. NF-kappa B is a transcription factor activated in response to a wide variety of inflammatory stimuli, including TNF, but whether leflunomide blocks NF-kappa B activation is not known. In the present report we demonstrate that treatment of a human T cell line (Jurkat) with leflunomide blocks TNF-mediated NF-kappa B activation in a dose- and time-dependent manner, with maximum inhibition at 5-10 microM. Inhibition was not restricted to TNF-induced activation, because leflunomide also inhibited NF-kappa B activation induced by other inflammatory agents, including phorbol ester, LPS, H2O2, okadaic acid, and ceramide. Leflunomide blocked the degradation of I kappa B alpha and subsequent nuclear translocation of the p65 subunit, steps essential for NF-kappa B activation. This correlated with inhibition of dual specificity-mitogen-activated protein kinase kinase as well as an Src protein tyrosine kinase, p56lck, by leflunomide. Reducing agents did not reverse the effect of leflunomide. Leflunomide also suppressed the TNF-activated NF-kappa B-dependent reporter gene expression. Our results thus indicate that leflunomide is a potent inhibitor of NF-kappa B activation induced by a wide variety of inflammatory stimuli, and this provides the molecular basis for its anti-inflammatory and immunosuppressive effects.
Similar articles
- Vesnarinone suppresses TNF-induced activation of NF-kappa B, c-Jun kinase, and apoptosis.
Manna SK, Aggarwal BB. Manna SK, et al. J Immunol. 2000 Jun 1;164(11):5815-25. doi: 10.4049/jimmunol.164.11.5815. J Immunol. 2000. PMID: 10820260 - Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis.
Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Manna SK, et al. J Immunol. 1999 Dec 15;163(12):6800-9. J Immunol. 1999. PMID: 10586080 - Leflunomide and malononitrilamides.
Silva Júnior HT, Morris RE. Silva Júnior HT, et al. Am J Med Sci. 1997 May;313(5):289-301. doi: 10.1097/00000441-199705000-00008. Am J Med Sci. 1997. PMID: 9145039 Review. - Genetic Variants of the NF-κB Pathway: Unraveling the Genetic Architecture of Psoriatic Disease.
Queiro R, Coto P, González-Lara L, Coto E. Queiro R, et al. Int J Mol Sci. 2021 Nov 30;22(23):13004. doi: 10.3390/ijms222313004. Int J Mol Sci. 2021. PMID: 34884808 Free PMC article. Review.
Cited by
- Concomitant Administration of Rosuvastatin and Lefleunamide in Low doses Synergize Against Complete Freunds Adjuvant (CFA)-Induced Rheumatoid Arthritis in Experimental Model.
Saeed AA, El-Shafey M, Helal GK, Akool ES. Saeed AA, et al. J Pharm Res Int. 2021;33(42A):370-382. doi: 10.9734/jpri/2021/v33i42a32415. Epub 2021 Aug 30. J Pharm Res Int. 2021. PMID: 39055998 Free PMC article. - Unleashing nature's potential and limitations: Exploring molecular targeted pathways and safe alternatives for the treatment of multiple sclerosis (Review).
Fathallah S, Abdellatif A, Saadeldin MK. Fathallah S, et al. Med Int (Lond). 2023 Aug 17;3(5):42. doi: 10.3892/mi.2023.102. eCollection 2023 Sep-Oct. Med Int (Lond). 2023. PMID: 37680650 Free PMC article. Review. - Composition and regulation of the immune microenvironment of salivary gland in Sjögren's syndrome.
Tan Z, Wang L, Li X. Tan Z, et al. Front Immunol. 2022 Sep 13;13:967304. doi: 10.3389/fimmu.2022.967304. eCollection 2022. Front Immunol. 2022. PMID: 36177010 Free PMC article. - Teriflunomide shifts the astrocytic bioenergetic profile from oxidative metabolism to glycolysis and attenuates TNFα-induced inflammatory responses.
Kabiraj P, Grund EM, Clarkson BDS, Johnson RK, LaFrance-Corey RG, Lucchinetti CF, Howe CL. Kabiraj P, et al. Sci Rep. 2022 Feb 23;12(1):3049. doi: 10.1038/s41598-022-07024-7. Sci Rep. 2022. PMID: 35197552 Free PMC article. - Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects.
Fischer S, Proschmann U, Akgün K, Ziemssen T. Fischer S, et al. Cells. 2021 Nov 15;10(11):3177. doi: 10.3390/cells10113177. Cells. 2021. PMID: 34831400 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous